AstraZeneca PLC (NYSE: AZN) Stock Competitors & Peer Comparison

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, LLY has a market cap of 1.3T. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while LLY trades at $1,417.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas LLY's P/E ratio is 44.98. In terms of profitability, AZN's ROE is +0.22%, compared to LLY's ROE of +0.84%. Regarding short-term risk, AZN is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for AZN.Check LLY's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, JNJ has a market cap of 657.6B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while JNJ trades at $273.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas JNJ's P/E ratio is 25.46. In terms of profitability, AZN's ROE is +0.22%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, AZN is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for AZN.Check JNJ's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, ABBV has a market cap of 521.1B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while ABBV trades at $294.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas ABBV's P/E ratio is 28.94. In terms of profitability, AZN's ROE is +0.22%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, AZN is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for AZN.Check ABBV's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, MRK has a market cap of 368.9B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while MRK trades at $149.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas MRK's P/E ratio is 46.58. In terms of profitability, AZN's ROE is +0.22%, compared to MRK's ROE of +0.05%. Regarding short-term risk, AZN is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for AZN.Check MRK's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, NVS has a market cap of 303.7B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while NVS trades at $160.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas NVS's P/E ratio is 18.51. In terms of profitability, AZN's ROE is +0.22%, compared to NVS's ROE of +0.25%. Regarding short-term risk, AZN is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for AZN.Check NVS's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, AMGN has a market cap of 251.9B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while AMGN trades at $466.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas AMGN's P/E ratio is 20.83. In terms of profitability, AZN's ROE is +0.22%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, AZN is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for AZN.Check AMGN's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, GILD has a market cap of 205.4B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while GILD trades at $170.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas GILD's P/E ratio is -424.67. In terms of profitability, AZN's ROE is +0.22%, compared to GILD's ROE of -0.22%. Regarding short-term risk, AZN is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for AZN.Check GILD's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, NVO has a market cap of 176.5B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while NVO trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas NVO's P/E ratio is 9.95. In terms of profitability, AZN's ROE is +0.22%, compared to NVO's ROE of +0.59%. Regarding short-term risk, AZN is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for AZN.Check NVO's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, PFE has a market cap of 173.9B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while PFE trades at $30.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas PFE's P/E ratio is 10.00. In terms of profitability, AZN's ROE is +0.22%, compared to PFE's ROE of +0.05%. Regarding short-term risk, AZN is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for AZN.Check PFE's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, BMY has a market cap of 127.6B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while BMY trades at $62.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas BMY's P/E ratio is 10.54. In terms of profitability, AZN's ROE is +0.22%, compared to BMY's ROE of +0.44%. Regarding short-term risk, AZN is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for AZN.Check BMY's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, SNY has a market cap of 106.2B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while SNY trades at $44.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas SNY's P/E ratio is 9.66. In terms of profitability, AZN's ROE is +0.22%, compared to SNY's ROE of +0.06%. Regarding short-term risk, AZN is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for AZN.Check SNY's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, GSK has a market cap of 99.2B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while GSK trades at $49.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas GSK's P/E ratio is 10.69. In terms of profitability, AZN's ROE is +0.22%, compared to GSK's ROE of +0.23%. Regarding short-term risk, AZN is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for AZN.Check GSK's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, BIIB has a market cap of 37.5B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while BIIB trades at $253.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas BIIB's P/E ratio is 16.01. In terms of profitability, AZN's ROE is +0.22%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, AZN is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for AZN.Check BIIB's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AZN's ROE is +0.22%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AZN is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for AZN.Check HZNP's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while GRFS trades at $8.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas GRFS's P/E ratio is 9.28. In terms of profitability, AZN's ROE is +0.22%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, AZN is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for AZN.Check GRFS's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while OGN trades at $13.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas OGN's P/E ratio is 4.13. In terms of profitability, AZN's ROE is +0.22%, compared to OGN's ROE of +0.22%. Regarding short-term risk, AZN is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for AZN.Check OGN's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, AMRN has a market cap of 249.4M. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while AMRN trades at $12.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas AMRN's P/E ratio is -120.60. In terms of profitability, AZN's ROE is +0.22%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, AZN is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for AZN.Check AMRN's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, MIRA has a market cap of 22.5M. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while MIRA trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas MIRA's P/E ratio is -0.37. In terms of profitability, AZN's ROE is +0.22%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, AZN is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for AZN.Check MIRA's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, SCLX has a market cap of 13M. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while SCLX trades at $1.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas SCLX's P/E ratio is -0.05. In terms of profitability, AZN's ROE is +0.22%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, AZN is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for AZN.Check SCLX's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, SCLXW has a market cap of 10.8M. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while SCLXW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AZN's ROE is +0.22%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, AZN is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for AZN.Check SCLXW's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AZN's ROE is +0.22%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AZN is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for AZN.Check CRXT's competition here

AstraZeneca PLC (NYSE: AZN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 289.7B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, AZN is priced at $186.65 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 20.17, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, AZN's ROE is +0.22%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, AZN is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for AZN.Check BDSIW's competition here